Department of infectious diseases and Molecular Techniques

Professor - Director: L. Skoura, eudoxia@med.auth.gr

Stuff

NHS Consultant:
SIDIROPOULOU ELENI, Microbiologist/Medical Biopathologist


A DIONYSOPOULOU SOFIA, Microbiologist/Medical Biopathologist

Technologist:
TASTEMIROGLOU SOULTANA

Medical and Biological Laboratories Assistants (MBLA):
SIDIROPOULOU FOTINI, KOUTRI AIKATERINI

History Aims

The laboratory supports antibody and antigen control against several microorganisms (viruses, bacteria, fungi and parasites) as well as their nucleic acid detection using molecular techniques.

We have been receiving samples from AHEPA University Hospital patients, other hospitals patients and a great number of outpatient samples for 25 years.

The laboratory also provides training to junior doctors and medical students and runs research projects. Our aim is to provide the best possible service to patients regarding infectious disease diagnoses and immunity control against significant pathogens, seeking quality in the applied laboratory assays, cooperation with clinical speciality physicians, as well as continuous education of medical and paramedical staff.

 

Laboratory work

Tests conducted in the laboratory include the identification of antibodies and antigens in biological fluids, and the detection and quantification of viral load or other microorganisms in those fluids.

For this purpose we perform enzyme immunoassays (EIA), such as Enzyme Linked Immunosorbent Assay (ELISA) and Chemiluminescent Microparticle Immunoassay (CMIA), indirect immunofluorescence (IIF), agglutination reactions, immunochromatography, immunoblotting (Western Blot) and polymerase chain reaction (PCR).

The laboratory is supported by the LIS information system.

 

Fields of performed tests

  • Antibody and antigen identification in peripheral blood and CSF in the diagnostic investigation and follow-up of hepatitides, HIV infection, cytomegalovirus (CMV), rubella virus and Toxoplasma gondii infections using CMIA methodology.

 

Type of assay

Methodology

HIV Ag-Ab

CMIA

HBsAg

CMIA

HBeAg

CMIA

Anti-HBs (results in IU/ml)

CMIA

Anti-Hbe

CMIA

Anti-HBc (IgG+IgM)

CMIA

Anti-HBc-IgM

CMIA

Anti-HCV (IgG+IgM)

CMIA

Anti-HAV (IgG) (qualitative)

CMIA

Anti-HAV-IgM

CMIA

Anti- IgG (results in IU/ml)

CMIA

Anti- Ig

CMIA

Anti-C.M.V. IgG

CMIA

Anti-C.M.V. IgM

CMIA

Antibodies against Rubella virus IgG (results in IU/ml)

CMIA

Antibodies against Rubella virus IgM

CMIA

Antibodies against Epstein- Barr virus (EBV) VCA IgG

CMIA

Antibodies against Epstein- Barr virus (EBV) VCA IgM

CMIA

 

  • Determination of IgG, IgM and IgA antibodies against hepatitis D (HDV), measles virus, mumps virus, adenoviruses Epstein Barr virus (EBV), Herpes Simplex virus (HSV) -, Respiratory Syncytial virus (RSV), Mycoplasma pneumoniae and Chlamydia spp.

 

Type of assay

Methodology

Anti-CMV IgM (Capture Elisa)

ELISA

Anti- HDV (IgG+IgM)

ELISA

Anti- HDV IgM

ELISA

HDAg

ELISA

Antibodies against Adenovirus IgA

ELISA

 

Antibodies against Adenovirus IgG

ELISA

 

Antibodies against Adenovirus IgM

ELISA

 

Antibodies against Respiratory Syncytial virus (RSV) IgA

ELISA

 

Antibodies against Respiratory Syncytial virus (RSV) IgG

ELISA

 

Antibodies against Respiratory Syncytial virus (RSV) IgM

ELISA

 

Antibodies against Herpes Simplex virus I-II (HSV I-II) gG

ELISA

 

Antibodies against Herpes Simplex virus I-II (HSV I-II) gM

ELISA

 

Antibodies against Varicella Zoster virus (VZV) IgG

ELISA

 

Antibodies against Varicella Zoster virus (VZV) Ig

ELISA

 

Antibodies against Measles virus IgG

 

ELISA

 

Antibodies against Measles virus Ig

ELISA

 

Antibodies against Mumps virus IgG

ELISA

 

Antibodies against Mumps virus IgM

ELISA

 

Antibodies against Mycoplasma pneumoniae IgA

ELISA

 

Antibodies against Mycoplasma pneumoniae IgG

ELISA

 

Antibodies against Mycoplasma pneumoniae Ig

ELISA

 

Antibodies against Chlamydia pneumoniae IgA

ELISA

 

Antibodies against Chlamydia pneumoniae IgG

ELISA

 

Antibodies against Chlamydia pneumoniae Ig

ELISA

 

 

 

  • Confirmation method for Hepatitis C

Type of assay

Methodology

Anti- HCV RIBA

 

Immunoblotting using recombinant proteins produced by E. coli on non-structural domains NS3, NS4 and high antigenicity peptides on structural domains C1, C2 and non-structural domain NS4.

 

 

  • Antibody detection and semiquantification using indirect immunofluorescence (IIF)

Type of assay

Methodology

Antibodies against Bartonellahenselae IgG

Indirect immunofluorescence (IIF)

Antibodies against Bartonellahenselae Ig

Indirect immunofluorescence (IIF)

Antibodies against Bartonella quintana IgG

Indirect immunofluorescence (IIF)

Antibodies against Bartonella quintana IgM

Indirect immunofluorescence (IIF)

Antibodies against Chlamydia pneum. IgG

Indirect immunofluorescence (IIF)

Antibodies against Chlamydia pneum. IgM

Indirect immunofluorescence (IIF)

Antibodies against Chlamydia psitt. IgG

Indirect immunofluorescence (IIF)

Antibodies against Chlamydia psitt. IgM

Indirect immunofluorescence (IIF)

Antibodies against Chlamydia trach. IgG

Indirect immunofluorescence (IIF)

Antibodies against Chlamydia trach. IgM

Indirect immunofluorescence (IIF)

Antibodies against Coxiella burnetii IgG phase I

Indirect immunofluorescence (IIF)

Antibodies against Coxiellaburnetii IgM phase I

Indirect immunofluorescence (IIF)

Antibodies against Coxiellaburnetii IgG phase II

Indirect immunofluorescence (IIF)

Antibodies against Coxiellaburnetii IgM phase II

Indirect immunofluorescence (IIF)

Antibodies against Rickettsiatyphi IgG

Indirect immunofluorescence (IIF)

Antibodies against Rickettsiatyphi IgM

Indirect immunofluorescence (IIF)

Antibodies against Rickettsiarickettsii IgG

Indirect immunofluorescence (IIF)

Antibodies against Rickettsia rickettsii IgM

Indirect immunofluorescence (IIF)

Antibodies against Legionella pneumophila (IgG+IgM)

Indirect immunofluorescence (IIF)

FTA - Abs for Treponema pallidum

Indirect immunofluorescence (IIF)

 

  • Antibody and antigen identification using rapid methods (Rapid tests)

 

Type of assay

Methodology

Antibodies against Helicobacter pylori

Immunochromatography

nti-HIV rapid test

Immunochromatography

Antibodies against Echinococcusgranulosus

Immunochromatography

Mono-Test

Immunochromatography

Legionella pneumophila urine antigen

Immunochromatography

Pneumococcus urine antigen (Streptococcus pneumoniae Ag)

Immunochromatography

 

  • Antibody identification using agglutination reactions and flocculation assays

 

Type of assay

Methodology

Widal (anti-Salmonella typhi O)

agglutination reaction

Widal (anti-Salmonella typhi H)

agglutination reaction

Wright (anti-Brucella abortus)

agglutination reaction

R.P.R.

flocculation assay

V.D.R.L.

flocculation assay

 

  • Molecular tests for the detection and quantification of viral load using the polymerase chain reaction method (PCR) for hepatitis B (HBV), hepatitis C (HCV), Herpesviridae and Polyoma viruses,ToxoplasmagondiiDNA detection and quantification.

Type of assay

Methodology

Hepatitis B virus (HBV)

Real time PCR

Hepatitis C virus (HCV)

Real time PCR

Cytomegalovirus (CMV)

Real time PCR

EpsteinBarr virus(EBV)

Real time PCR

Herpes simplex virus I/I (HSV)

Real time PCR

Varicella zoster virus (VZV)

Real time PCR

Polyoma virus (JCV/BK)

Real time PCR

oxoplasma gondii

Real time PCR

 

Instructions

SAMPLE TYPE

a) Antigen-antibody detection.

- blood serum (tube without anticoagulant)

- CSF (cerebrospinal fluid)

- urine (unprocessed)

The quantities required range between 400 and 600 l for CMIA methodology, depending of the number of requested tests, approximately 500 l for ELISA methodology and indirect immunofluorescence and approximately 1ml unprocessed urine.

b) Molecular techniques

Hepatitis B virus (HBV) and hepatitis C virus (HCV): Blood serum (1200l serum derived from approximately 6 ml whole blood without anticoagulant).

Cytomegalovirus (CMV): Urine in suspicion of primary infection, CSF, bronchoalveolar lavage (BAL), amniotic fluid, plasma, tissue specimen, scrapings or any biological fluid, depending on the lesions.

Epstein Barr virus (EBV): Blood serum or plasma (derived from 2.5 ml of blood with EDTA or Sodium citrate) or tissue specimen (in a sterile container without formalin or any other conservative added).

Herpes simplex virus I-II (HSV) and Varicella zoster virus (VZV): CSF, blood serum, plasma, tissue specimen or any biological fluid, depending on the lesions.

oxoplasma gondii: whole blood (full blood count tube with EDTA), CSF or amniotic fluid.

Polyoma virus (JCV/BK): CSF, urine or blood serum.

 

ACQUIRING AND SENDING SAMPLES

Samples intended to be sent for molecular testing should be acquired carefully. Blood sampling should not be performed using powdered gloves. The skin must have dried thoroughly from the alcoholic solution applied prior to blood sampling. Heparin use as an anticoagulant is prohibited. Talc, ethanol and heparin are test inhibitors.

In order to detect an infection, samples should be acquired as early as possible, in the early disease stages.

It is necessary for the disease day and other clinical information to be provided, so as to evaluate the test results.

When two serum samples are sent, there should be a 2-3 week time interval between first and second blood sampling.

Samples intended for molecular testing should be sent on the same day, otherwise they should be frozen. For the remaining tests, samples are sent on the same day or stay preserved in refrigerator temperature. When sending samples from other hospitals, they must be carried in containers with ice packs.

 

BLOOD SAMPLING DAYS AND SAMPLE SENDING

Working days during morning hours

Anyone interested in receiving further information is invited to contact us at the department telephone number.


Access Diagram

Access Diagram to Laboratory
Laboratory

Lab Diagram

Access Diagram to Laboratory
Laboratory